Searched for
DRUG DISCOVERY INDIA
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...- Rasayan Labs launches AI-native drug discovery platform at ICT MumbaiIn an exciting development, Rasayan Labs has unveiled a groundbreaking AI-based platform to enhance computational chemistry and drug discov...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhat is needed in the markets these days is realism. Not fear or gloom, but a clear-eyed acceptance of where things actually stand. Realism...
- Models ready but data isn’t: Google’s Andi Gutmans on AI’s next big hurdleAs companies increasingly deploy AI, Google emphasises the importance of preparing corporate data for effective use. Andi Gutmans stated th...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsThere are times when a watchlist is more important than a buy list. But if you still insist on putting money in the market, look at fundame...
- Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil PatelZydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to f...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacityAragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-mol...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsAs an investor, what you need to do at this point of time is this: A bit of extra work in terms of stock-picking so that you avoid anxiety ...
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplierIndia's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial firs...
- Stone Age high: Ancient Indonesian foragers may have sucked on mind-altering nuts 25,000 years ago, study findsAncient foragers on Sulawesi island used mind-altering betel nuts approximately 25,000 years ago. Analysis of prehistoric teeth revealed ch...
- Airlines directed by DGCA to test all pilots following Air India drugs row, report saysThe move follows an unusual incident involving an Air India-operated Airbus SE A320, in which all three hydraulic systems failed. Such a si...
- AI's biggest business value lies in solving problems that companies didn't know how to solve: Anthropic India MDArtificial intelligence offers significant business value by solving complex problems. Frontier AI models create the most value when applie...
- Amazon, Flipkart's multi-front war; India set for more GCCsHappy Wednesday! Amazon and Flipkart have broadened their bets as quick commerce platforms chip away at their share of user base. This and ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIn the equity market, it is generally good to keep one eye on risk management. But there are times when it becomes a must-do. We are curren...
- Convening India's brightest minds: The Bharat Life Sciences Award’s Innovation Summit to spotlight life sciencesIndia sets its sights on becoming a frontrunner in innovation within the life sciences arena. The Bharat Life Sciences Award 2026 aims to h...
- Aragen Life Sciences files draft papers with Sebi to raise funds through IPOAragen Life Sciences has filed its DRHP with Sebi for an IPO comprising a Rs 800 crore fresh issue and an OFS. Proceeds will fund debt repa...
- ETMarkets Smart Talk | Two-year market consolidation may set stage for next bull run: UTI AMC’s Ajay TyagiTyagi, however, remains cautious on pockets of the mid- and small-cap universe, where valuations are above long-term averages. He sees larg...
- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
Load More
